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Russian Roulette with Clopidogrel

Liviya Thoreson, D.O.
Anthony Worsham, M.D.
Department of Internal Medicine

Clopidogrel Overdose: A Case Report and Literature Review
DISCUSSION

INTRODUCTION:
• Clopidogrel is an antiplatelet agent commonly prescribed for acute coronary, peripheral
vascular disease and prevention of thrombotic events. As it was among the highest of
prescription drug sales in the US in 2011, hospitalists should be prepared to encounter
and manage overdoses.
• Here we describe an unusual case of a clopidogrel overdose and the discovery that
despite its frequent use, the literature is quite barren of case reports and discussion
regarding the monitoring and management of potentially fatal hemorrhage.
CASE INFORMATION

Clopidogrel is a thienopyradine which prevents ADP from binding to the P2Y12
receptor; by doing so, it inhibits platelet activation and therefore, platelet
aggregation. This inhibition is irreversible and lasts for the lifespan of platelets (7-10
days). Clopidogrel is a pro-drug with a half-life of 6 hours, but its active metabolite
has a half-life of 30 minutes. There is little literature regarding overdose and no
published data on using either platelet function assays or aggregation studies in
overdose. Only two case reports could be found documenting clopidogrel overdoses.

• Clopidogrel is very commonly prescribed, ranked amongst the highest of
prescription drug sales in 2011.
• Given its popularity, the lack of reported overdoses in the literature is surprising.
• There still remains very little guidance regarding management and monitoring of
clopidogrel overdose.

CASE REPORTS

HISTORY:

• A 54-year-old woman with hyperlipidemia and prior transient ischemic attack (TIA) two
months prior presented to our hospital with vaginal bleeding and hematuria. Admitted to
having intentionally overdosed on a study drug 12 hours earlier.
• She was diagnosed with possible TIA two months prior after presenting with right-sided
weakness and dysarthria resolving after 4 hours. She was enrolled in the PlateletOriented Inhibition in New TIA (POINT) trial, a large ongoing, multi-centered, doubleblinded, randomized controlled study, which seeks to determine if clopidogrel prevents
major ischemic events within 90 days of a TIA.
• Consumed 30 study drug pills (placebo vs clopidogrel) following a domestic argument
and binge drinking. She was also on aspirin 162 mg daily and atorvastatin. She denied
suicidality.
• The POINT study team unblinded the study drug, which was clopidogrel.
LABS:
3
3
10 /mm

and normal hemoglobin and INR.
• Platelet count of 245 x
• Platelet function assay was abnormal with prolongation of closure times above 300 sec.
HOSPITAL COURSE:

• On hospital day 3, the patient’s vaginal bleeding resolved, her blood counts were stable,
and she was discharged to Psychiatry.
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CONCLUSIONS

Case One:
Kocabay et al (2006), Turkey
49 yo M, Suicide Attempt
- Overdosed on 1,650 mg clopidogrel
- Asymptomatic & No Bleeding
- Normal vitals & lab results
- Platelet Aggregation Tests over 7 days
showed decreased aggregation
fractions which recovered over the
week.

From what we learned in our case and from the
related literature review, we propose that in
situations of clopidogrel overdose, a conservative
approach be taken:
• Serial monitoring of blood counts
• Platelet & RBC transfusions, if needed
• Platelet testing/ functional monitoring is
probably unnecessary in most cases

Case Two:
Claua et al (2009), Spain
49 yo F, Suicide Attempt
- Overdosed on 1,875 mg clopidogrel
- HR 101, BP 150/95, RR 22 O2
- Hgb= 10.4 & Hct= 31
- CT Chest: Pulmonary hemorrhage
and hemothorax
- Required thoracentesis (200mL) +
transfusions
- Recovered & discharged after 11 days
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